107 related articles for article (PubMed ID: 23406770)
21. Direct effects of neuroleptics on the activity of CYP2A in the liver of rats.
Haduch A; Wójcikowski J; Daniel WA
Pharmacol Rep; 2005; 57(6):867-71. PubMed ID: 16382210
[TBL] [Abstract][Full Text] [Related]
22. Formation of sulfone metabolites from chlorpromazine and perazine in man.
Breyer-Pfaff U; Kreft H; Rassner H; Prox A
Drug Metab Dispos; 1978; 6(2):114-9. PubMed ID: 26524
[TBL] [Abstract][Full Text] [Related]
23. Effect of carbamazepine on the pharmacokinetics of promazine.
Syrek M; Wójcikowski J; Daniel W
Pol J Pharmacol; 1996; 48(6):601-8. PubMed ID: 9112700
[TBL] [Abstract][Full Text] [Related]
24. Examination of iron (III) and hexacyanoferrate (III) ions as reagents for the spectrophotometric determination of promazine and perazine.
Misiuk W; Kuźmicka L; Mielech K; Puzanowska-Tarasiewicz H
Acta Pol Pharm; 2001; 58(6):421-5. PubMed ID: 12197613
[TBL] [Abstract][Full Text] [Related]
25. Metabolism and CYP-inducer properties of astaxanthin in man and primary human hepatocytes.
Kistler A; Liechti H; Pichard L; Wolz E; Oesterhelt G; Hayes A; Maurel P
Arch Toxicol; 2002 Jan; 75(11-12):665-75. PubMed ID: 11876499
[TBL] [Abstract][Full Text] [Related]
26. Characterization of the cytochrome P450 isoenzymes involved in the in vitro N-dealkylation of haloperidol.
Pan LP; Wijnant P; De Vriendt C; Rosseel MT; Belpaire FM
Br J Clin Pharmacol; 1997 Dec; 44(6):557-64. PubMed ID: 9431831
[TBL] [Abstract][Full Text] [Related]
27. Follow-up to the pre-validation of a harmonised protocol for assessment of CYP induction responses in freshly isolated and cryopreserved human hepatocytes with respect to culture format, treatment, positive reference inducers and incubation conditions.
Abadie-Viollon C; Martin H; Blanchard N; Pekthong D; Bachellier P; Mantion G; Heyd B; Schuler F; Coassolo P; Alexandre E; Richert L
Toxicol In Vitro; 2010 Feb; 24(1):346-56. PubMed ID: 19497360
[TBL] [Abstract][Full Text] [Related]
28. Main contribution of the cytochrome P450 isoenzyme 1A2 (CYP1A2) to N-demethylation and 5-sulfoxidation of the phenothiazine neuroleptic chlorpromazine in human liver--A comparison with other phenothiazines.
Wójcikowski J; Boksa J; Daniel WA
Biochem Pharmacol; 2010 Oct; 80(8):1252-9. PubMed ID: 20615392
[TBL] [Abstract][Full Text] [Related]
29. Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
Bakken GV; Molden E; Knutsen K; Lunder N; Hermann M
Drug Metab Dispos; 2012 Sep; 40(9):1778-84. PubMed ID: 22688609
[TBL] [Abstract][Full Text] [Related]
30. The activity of cytochrome P450 CYP2B in rat liver during neuroleptic treatment.
Haduch A; Wójcikowski J; Daniel WA
Pharmacol Rep; 2007; 59(5):606-12. PubMed ID: 18048963
[TBL] [Abstract][Full Text] [Related]
31. Characterization of human cytochrome p450 enzymes involved in the metabolism of the piperidine-type phenothiazine neuroleptic thioridazine.
Wójcikowski J; Maurel P; Daniel WA
Drug Metab Dispos; 2006 Mar; 34(3):471-6. PubMed ID: 16272405
[TBL] [Abstract][Full Text] [Related]
32. Simultaneous assessment of cytochrome P450 activity in cultured human hepatocytes for compound-mediated induction of CYP3A4, CYP2B6, and CYP1A2.
Rhodes SP; Otten JN; Hingorani GP; Hartley DP; Franklin RB
J Pharmacol Toxicol Methods; 2011; 63(3):223-6. PubMed ID: 21111054
[TBL] [Abstract][Full Text] [Related]
33. Possible mutagenicity of the psychoactive phenothiazine derivative perazine in vivo and in vitro.
Madle S; Obe G; Schroeter H; Herha J; Pietzcker A
Hum Genet; 1980; 53(3):357-61. PubMed ID: 6102962
[TBL] [Abstract][Full Text] [Related]
34. Effect of neuroleptics on cytochrome P450 2C11 (CYP2C11) in rat liver.
Haduch A; Wójcikowski J; Daniel WA
Pharmacol Rep; 2011; 63(6):1491-9. PubMed ID: 22358097
[TBL] [Abstract][Full Text] [Related]
35. Inhibitory effect of phenothiazines on the binding of [3H]perazine to alpha 1-acid glycoprotein.
Schley J
J Pharm Pharmacol; 1987 Feb; 39(2):132-4. PubMed ID: 2881999
[TBL] [Abstract][Full Text] [Related]
36. The induction of CYP1A2, CYP2D6 and CYP3A4 by six trade herbal products in cultured primary human hepatocytes.
Hellum BH; Hu Z; Nilsen OG
Basic Clin Pharmacol Toxicol; 2007 Jan; 100(1):23-30. PubMed ID: 17214607
[TBL] [Abstract][Full Text] [Related]
37. Pharmacological studies on perazine and its primary metabolites.
Brand U; Menge HG; Neumann BW; Stille G
Pharmacopsychiatry; 1989 Nov; 22(6):255-7. PubMed ID: 2575764
[TBL] [Abstract][Full Text] [Related]
38. Cytochrome P450-mediated metabolism of triclosan attenuates its cytotoxicity in hepatic cells.
Wu Y; Chitranshi P; Loukotková L; Gamboa da Costa G; Beland FA; Zhang J; Fang JL
Arch Toxicol; 2017 Jun; 91(6):2405-2423. PubMed ID: 27896399
[TBL] [Abstract][Full Text] [Related]
39. [Metabolism and excretion of the neuroleptic drug perazine in healthy volunteers].
Schley J; Riedel E; Müller-Oerlinghausen B
Int Pharmacopsychiatry; 1981; 16(4):201-11. PubMed ID: 6121765
[TBL] [Abstract][Full Text] [Related]
40. Phenobarbital-induced prolongation of half-life and alteration of distribution of a phenothiazine drug metabolite in the rat.
Breyer U; Junginger W; Villumsen D
Biochem Pharmacol; 1976 Dec; 25(23):2623-9. PubMed ID: 10928
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
